Sinocelltech Group Ltd. (688520.SH) Latest Company News

Oct 30, 2026, 11:14 UTC
Shenzhou Cell reported revenue of 892 million yuan and a net loss attributable to shareholders of 644 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 30, 2026, 11:14 UTC
Shenzhou Cell reported third-quarter 2026 revenue of 232 million yuan, down 31.61% year over year, and a net loss attributable to shareholders of 278 million yuan.
Source:
- finance.sina.cn
Oct 13, 2026, 14:24 UTC
Ten A-share listed companies disclosed plans to reduce their holdings; no listed company disclosed a planned increase in holdings that day.
Source:
- finance.sina.cn
Oct 13, 2026, 12:37 UTC
Shenzhou Cell announced that employee shareholding platforms Shenzhou Anlong and Shenzhou Anqian plan to sell up to 56,700 and 76,600 shares, respectively, through centralized bidding, totaling no more than 133,300 shares or 0.03% of the company’s total share capital.
Source:
- finance.sina.cn
Oct 12, 2026, 12:01 UTC
China's National Medical Products Administration approved a clinical trial of SCT810 injection, developed by Shenzhou Cell Engineering, for patients with moderate-to-severe hemophilia A or hemophilia B, with or without inhibitors.
Source:
- finance.sina.cn
Sep 13, 2026, 11:45 UTC
Four shareholders of Sinocelltech plan to reduce their combined stake by no more than 0.94%.
Source:
- wap.eastmoney.com
Sep 13, 2026, 07:32 UTC
Four shareholder and employee stock ownership platforms of Sino Biological announced plans to collectively reduce their stake in the company by no more than 0.94% of total shares between October 13, 2026 and January 12, 2027.
Source:
- finance.sina.cn
Aug 28, 2026, 09:17 UTC
SinoCell Technologies reported a net loss of 366 million yuan for the first half of 2026, compared with a loss of 33.77 million yuan in the same period of 2025.
Source:
- finance.sina.cn
Aug 19, 2026, 09:10 UTC
Sinocelltech's controlled subsidiary Sinocelltech Engineering received approval from China's National Medical Products Administration to conduct clinical trials for its SCTB10 injection in hemophilia A.
Source:
- finance.sina.cn
- m.21jingji.com

688520.SH

Shenzhou Cell reported revenue of 892 million yuan and a net loss attributable to shareholders of 644 million yuan for the first three quarters of 2026.

Shenzhou Cell reported third-quarter 2026 revenue of 232 million yuan, down 31.61% year over year, and a net loss attributable to shareholders of 278 million yuan.

Ten A-share listed companies disclosed plans to reduce their holdings; no listed company disclosed a planned increase in holdings that day.

Shenzhou Cell announced that employee shareholding platforms Shenzhou Anlong and Shenzhou Anqian plan to sell up to 56,700 and 76,600 shares, respectively, through centralized bidding, totaling no more than 133,300 shares or 0.03% of the company’s total share capital.

China's National Medical Products Administration approved a clinical trial of SCT810 injection, developed by Shenzhou Cell Engineering, for patients with moderate-to-severe hemophilia A or hemophilia B, with or without inhibitors.

Four shareholders of Sinocelltech plan to reduce their combined stake by no more than 0.94%.

Four shareholder and employee stock ownership platforms of Sino Biological announced plans to collectively reduce their stake in the company by no more than 0.94% of total shares between October 13, 2026 and January 12, 2027.

SinoCell Technologies reported a net loss of 366 million yuan for the first half of 2026, compared with a loss of 33.77 million yuan in the same period of 2025.

Sinocelltech's controlled subsidiary Sinocelltech Engineering received approval from China's National Medical Products Administration to conduct clinical trials for its SCTB10 injection in hemophilia A.